Chemomab Therapeutics (CMMB) Accumulated Expenses (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Accumulated Expenses data on file, last reported at $656000.0 in Q4 2025.

• Quarterly Accumulated Expenses fell 57.29% year-over-year to $656000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $656000.0 (down 57.29% YoY) and the FY2025 annual result came in at $656000.0, down 57.29% from the prior year.
• Accumulated Expenses grew to $656000.0 in Q4 2025, from $464000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.4 million in Q4 2023 to a low of $464000.0 in Q3 2025.
• A 5-year average of $1.9 million and a median of $1.8 million in 2021 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 417.3% — and 2025, when it plunged 85.15%.
• Tracing CMMB's Accumulated Expenses over 5 years: stood at $653000.0 in 2021, then soared by 417.3% to $3.4 million in 2022, then increased by 1.33% to $3.4 million in 2023, then tumbled by 55.13% to $1.5 million in 2024, then sank by 57.29% to $656000.0 in 2025.
• The last three Accumulated Expenses figures came in at $656000.0 (Q4 2025), $464000.0 (Q3 2025), and $666000.0 (Q2 2025), per Business Quant data.